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Semantic integration of clinical laboratory tests from electronic
health records for deep phenotyping and biomarker discovery
Xingmin Aaron Zhang 1, Amy Yates 2, Nicole Vasilevsky 2,3, J. P. Gourdine2,4, Tiffany J. Callahan 5, Leigh C. Carmody 1,
Daniel Danis 1, Marcin P. Joachimiak6, Vida Ravanmehr1, Emily R. Pfaff7, James Champion7, Kimberly Robasky7,8,9, Hao Xu10,
Karamarie Fecho 10, Nephi A. Walton11, Richard L. Zhu12, Justin Ramsdill2, Christopher J. Mungall6, Sebastian Köhler 13,14,
Melissa A. Haendel2,3,15, Clement J. McDonald16, Daniel J. Vreeman 17,18, David B. Peden7,19,20, Tellen D. Bennett 21,
James A. Feinstein 22, Blake Martin21, Adrianne L. Stefanski5, Lawrence E. Hunter 5, Christopher G. Chute 12 and
Peter N. Robinson 1,23
Electronic Health Record (EHR) systems typically define laboratory test results using the Laboratory Observation Identifier Names
and Codes (LOINC) and can transmit them using Fast Healthcare Interoperability Resource (FHIR) standards. LOINC has not yet been
semantically integrated with computational resources for phenotype analysis. Here, we provide a method for mapping LOINC-
encoded laboratory test results transmitted in FHIR standards to Human Phenotype Ontology (HPO) terms. We annotated the
medical implications of 2923 commonly used laboratory tests with HPO terms. Using these annotations, our software assesses
laboratory test results and converts each result into an HPO term. We validated our approach with EHR data from 15,681 patients
with respiratory complaints and identified known biomarkers for asthma. Finally, we provide a freely available SMART on FHIR
application that can be used within EHR systems. Our approach allows readily available laboratory tests in EHR to be reused for
deep phenotyping and exploits the hierarchical structure of HPO to integrate distinct tests that have comparable medical
interpretations for association studies.
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INTRODUCTION
Electronic health records (EHRs) have been widely adopted in US
hospitals since the Health Information Technology for Electronic
and Clinical Health Act (HITECH) was passed in 2009, and offer an
unprecedented opportunity to accelerate translational research
because of advantages of scale and cost efficiency as compared
with traditional cohort-based studies.1 In particular, EHRs contain
rich phenotype information that can be utilized to stratify diseases
and to develop hypotheses. For instance, phenome-wide associa-
tion studies (PheWAS) can exploit EHR data to define case–control
cohorts for disease diagnoses or laboratory traits and then analyze
associations with hundreds of thousands of genetic variants.2–4
Despite the great potential of EHR data, patient phenotyping from
EHRs is still challenging because the phenotype information is
distributed in many EHR locations (laboratories, notes, problem
lists, imaging data, etc.) and since EHRs have vastly different
structures across sites. This lack of integration represents a
substantial barrier to widespread use of EHR data in translational
research.
Laboratory tests provide a critical resource for phenotype
extraction. Deep phenotyping, i.e., comprehensive and precise
phenotyping of individual disease manifestations, is an essential
component of precision medicine and could potentially extend
the reach of PheWAS studies.5,6 Laboratory tests have broad
applicability for translational research, but EHR-based research
using laboratory data have been challenging because of their
diversity and the lack of standardization of reporting laboratory
test results. For instance, some tests measure nitrite level in urine
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using an automated machine, whereas others use a test strip.
Some report the value in mg/dL, whereas others report a
qualitative value of positive/negative. If any of these tests were
abnormal, the medical interpretation would be that nitrituria is
present, yet current informatics frameworks do not easily support
such inferences. Therefore, substantial challenges exist for
standardization and integration of laboratory data for deep
phenotyping and EHR-based translational research.
Recent advances in the standardization of EHR systems and
phenotype ontologies make it feasible to extract patient
phenotypes from laboratory tests at a large scale. The Fast
Healthcare Interoperability Resource (FHIR) was introduced in
2013 and provides a standardized interface to individual EHR
systems for healthcare-related data.7 FHIR separates healthcare-
related data into granular components as “resources” such as
observation, medication, patient identity and insurance claims,
which have a standard definition and associated semantic
bindings, which can be computationally integrated even when
they are created by different methods and organizations.
Laboratory tests, encoded as observations in FHIR, are uniquely
identified with Laboratory Observation Identifier Names and
Codes (LOINC), which is a universal code system that defines
various kinds of clinical laboratory tests and other measurements
(~86,000 entries).8 The outcome of a FHIR observation can be
represented by a term in the Human Phenotype Ontology (HPO),
which is a logically defined vocabulary for describing medically
relevant abnormal phenotypes.9 The HPO has become the de
facto standard for computational phenotype analysis in genomics
and rare disease.10–12 The HPO currently contains 14,184 terms
(February, 2019) including a comprehensive representation of
laboratory abnormalities such as hyperglycemia, thrombocytope-
nia, nitrituria, and increased urine alpha-ketoglutarate concentra-
tion. Here, we present a computational method that semantically
harmonizes FHIR, LOINC, and HPO. The software rolls up LOINC
terms for tests whose outcomes are medically comparable into
common categories and interprets the outcome as HPO terms,
thereby automatically extracting detailed, deep phenotypic
profiles of laboratory results for downstream studies.
RESULTS
Overview of strategy
We present an approach to mapping the outcomes of laboratory
tests as encoded in EHRs with LOINC terms for the tests and FHIR
Observation resources representing the test results as HPO terms.
A LOINC term by itself does not specify the outcome of a test. But
if the outcome of a test (such as “high” or “low”) and the nature of
the test are known, we can then infer the phenotypic abnormality.
For example, LOINC 32710-6 “Nitrite [Presence] in Urine” together
with the outcome “positive” implies the phenotypic abnormality
Nitrituria (HP:0031812).
LOINC-coded laboratory tests can be grouped broadly into
three categories, those with a quantitative outcome (Qn), an
ordered categorical outcome (ordinal, or Ord) and an unordered
categorical outcome (nominal, or Nom). A quantitative test for an
analyte has a normal range, and there are three types of mappings
depending on the result of the test: L (lower than normal), N
(normal), and H (higher than normal). Take, for instance, a test
for the concentration of potassium in the blood (LOINC:6298-4,
Fig. 1a). If the result is high, our procedure infers the correspond-
ing HPO term for Hyperkalemia (HP:0002153). Analogously, a low
result is mapped to Hypokalemia (HP:0002900). The HPO is an
ontology of abnormal phenotypes, and thus there is no term that
specifically represents a normal test result. However, computa-
tional analysis can record negated HPO terms, and the normal test
result is represented as NOT Abnormal blood potassium
concentration (HP:0011042).
Ordinal tests can have a series of ordered outcomes.
The majority of the ordinal LOINC tests were mapped to two
possible outcomes, POS (positive) or NEG (negative). For instance,
the result of the test Nitrite in urine by test strip can be positive
(present) or negative (absent) (Fig. 1a). If present, then our
approach infers the HPO term Nitrituria (HP:0031812); if absent,
our approach infers NOT Nitrituria (HP:0031812).
Nominal tests have a series of outcomes that lack a natural
ordering. Yet, some nominal result values are considered
abnormal. For instance, LOINC 5778-6, color of urine. Currently,
nine abnormal results of this test are mapped to the nine child
terms of abnormal urinary color (HP:0012086), including red urine
(HP:0040318) and dark urine (HP:0040319).
A LOINC to HPO mapping library
We have mapped 2923 LOINC terms to HPO terms. In all, 80.4%
of the mapped LOINC tests are Qn, 18.8% Ord, and 0.8% Nom
(Fig. 2a). Taken together, these LOINC terms mapped to a total of
719 distinct HPO terms. We analyzed the distribution of the
number of distinct LOINC terms that were mapped to an
individual HPO term. In 54.8% of the cases, two or more LOINC
terms are mapped to the same HPO term (mean 7.5) (Fig. 2b),
reflecting the fact that multiple laboratory tests (and associated
LOINC terms) have outcomes that we consider to have an
equivalent clinical interpretation.
Algorithm for converting LOINC-coded laboratory tests into HPO-
coded phenotypes
We designed an algorithm that inspects elements of a FHIR
resource for laboratory tests and converts the outcome into an
HPO term. A standard FHIR resource for laboratory tests (a FHIR
Observation) contains patient information, test identification, test
result, normal reference ranges, and interpretations (Fig. 1b). The
algorithm compares the numerical result with the normal
reference ranges to assign an interpretation code such as “L” or
“POS” (Table 1), or make use of the interpretation codes when they
are present, to map the result to the corresponding HPO term
(Supplementary Fig. 1). Overall, the algorithm handles all three
major types of LOINC-coded laboratory tests (Qn, Ord, and Nom)
when combined with the LOINC to HPO annotation data.
HPO on FHIR
To demonstrate conversion of FHIR-encoded LOINC tests into
HPO, we created a SMART on FHIR application that uses the
mapping library. SMART (Substitutable Medical Applications,
Reusable Technologies) on FHIR is an application platform for
EHRs that allows applications to run on different FHIR-enabled EHR
systems.13 Our application, HPO on FHIR, transforms a bundle of
laboratory observations for a patient into a list of HPO codes
(Fig. 3). We have also developed a command-line application that
can iterate through all laboratory tests in a FHIR-enabled server,
convert each into an HPO term and store them in a relational
database for translational research.
LOINC to HPO demonstration with asthma
To test our method for semantic integration of laboratory tests, we
analyzed a de-identified EHR dataset from the University of North
Carolina (UNC) comprising 15,681 patients who had a history of
asthma or asthma-like symptoms. The cohort is skewed toward
female (58.9%) and older patients (median age: 61.5 years, Fig. 4a).
The median tracking period of patients in this cohort is 3.1 years.
The dataset contains ~54 million records of LOINC-encoded clinical
test results, medication prescriptions, diagnosis codes, procedure
codes, patient information, and other supporting records (Fig. 4b).
Using our LOINC to HPO conversion algorithm, we successfully
transformed 9.9 out of 11 million (88.6%) laboratory tests into HPO
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terms (Fig. 4c). For the entire cohort, on average, each HPO term was
mapped from 1.8 distinct types of laboratory tests (Fig. 4d),
indicating that the transformation successfully integrated distinctly
coded laboratory tests that have the same clinical interpretation. The
mapping procedure assigned an average of 633 laboratory test-
derived HPO terms per individual patient, many of which were from
the same laboratory tests performed at different visits. The tests
corresponded to a mean of 57.7 unique HPO terms, of which 20.8
were abnormalities and the remainder were normal phenotypes
(Fig. 4e). The hierarchical structure of the HPO allows inferences to
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be propagated up to parent terms and their ancestors;14 using this
method, we inferred an additional 51.2 HPO terms (total 73.5) based
on 22.2 abnormalities for each patient (Supplementary Fig. 2).
As a proof-of-principle, we tested the ability of our procedure to
identify phenotypic abnormalities associated with a diagnosis of
asthma or with frequent prednisone use. About one-third of the
patients in this cohort had an ICD 9/10 diagnosis of asthma, and
the remaining patients had ICD 9/10 codes reflecting other,
potentially asthma-like, respiratory complaints. In all, 14.2% of
patients who had a diagnosis of asthma were administered or
prescribed prednisone >3 times within a tracking period between
2004 and 2016; 8.5% of the remaining patients had been
administered prednisone more than three times. Prednisone is a
corticosteroid drug used for severe asthma treatment with
multiple other indications.15 We reasoned that both the diagnosis
of asthma and the history of treatment with prednisone would
likely be correlated with different but overlapping sets of
laboratory abnormalities. Using logistic regression, we assessed
the contribution of frequent prednisone prescription and the
presence of acute asthma diagnosis to each phenotypic
abnormality.
Prednisone usage was significantly associated with an increased
odds ratio for exhibiting many abnormal phenotypes that are
consistent with the known effects of prednisone (Table 2), such as
hypoalbuminemia (HP:0003073),16 neutrophilia (HP:0011897),17
monocytosis (HP:0012311),18 leukocytosis (HP:0001974),18 hypo-
kalemia (HP:0002900),19 and elevated serum creatine phosphoki-
nase (HP:0003236).20 An acute asthma diagnosis was significantly
associated with seven phenotypes, abnormal metabolism
(HP:0032245), abnormality of vitamin metabolism (HP:0100508),
increased red blood cell count (HP:0020059), increased VLDL
cholesterol concentration (HP:0003362), and eosinophilia
(HP:0001880), and two ancestor terms of eosinophilia, abnormal
eosinophil count (HP:0020064), and abnormal eosinophil mor-
phology (HP:0001879). Eosinophilia is a well-established marker
for acute allergic asthma.21 Several studies have linked vitamin A,
B, C, D, E with asthma.22–24 In this study, we applied a threshold
minimum number of patients before performing statistical
analysis, and none of the specific subtypes of abnormality of
vitamin metabolism (HP:0100508; n= 111 patients) passed this
threshold. However, a number of patients were found to have
increased blood folate (HP:0040087; n= 33 patients), vitamin B12
deficiency (HP:0200502; n= 6 patients), low serum calciferol
(HP:0012053; n= 56 patients), and low serum calcitriol
(HP:0012052; n= 6 patients). Thus, the hierarchical structure of
HPO allowed us to infer the parent phenotype (Abnormality of
vitamin metabolism) and aggregate enough data to find that it is
associated with acute asthma diagnosis (Supplementary Fig. 3).
The term abnormal metabolism (HP:0032245) was also flagged,
but this was solely related to the 111 patients annotated to
abnormality of vitamin metabolism, which is a child term of
abnormal metabolism. Although there have been some conflicting
results,25 a number of studies have shown a positive correlation
between increased total, high- or low density lipoprotein
cholesterol, or triglycerides (Supplementary Fig. 2) and
asthma.26–30 An increased red blood cell count is not a recognized
biomarker of asthma, but could conceivably reflect a number of
factors including hypoxemia (11.1% with an acute asthma
diagnosis also had a chronic obstructive pulmonary disease
diagnosis), or hemoconcentration resulting from acute dehydra-
tion during an asthma attack, but the nature of this retrospective
study does not allow us to consult the full medical records to
investigate this.
Fig. 1 Semantic integration of LOINC-coded laboratory tests in FHIR into HPO terms. a Representative examples of LOINC to HPO mapping.
Potassium in blood, a quantitative (Qn) LOINC test, has three potential outcomes, L (lower than normal), N (normal), and H (higher than
normal) and is mapped to three corresponding HPO terms. Presence of nitrite in urine, an ordinal (Ord) test, has two possible outcomes, POS
(positive) or NEG (negative) and is mapped to either Nitrituria (HP:0031812) or NOT Nitrituria (HP:0031812), respectively. Color of urine, a
nominal (Nom) test, has a list of likely outcomes (represented as Systematized Nomenclature of Medicine-Clinical Terms [SNOMED-CT] codes
using the SNOMED-CT US extension) and each one is mapped to an HPO term. b Schematic representation of the relevant contents of a FHIR
observation for laboratory tests. Each FHIR Observation resource for a LOINC-encoded laboratory test includes an identifier (id) and the name
of the patient, the LOINC code and name, the normal reference range and the observed value as well as an interpretation of the result (see
Table 1 for a complete list)
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Table 1. FHIR codes for test outcomes
Primary code Other FHIR codes mapped Meaning
A AA, W Abnormal
L <, D, LL, LU Lower
than normal
N B, I Normal
H >, HH,HU, U Higher
than normal
NEG ND, NR Not present
POS AC, DET, RR, TOX, WR Present
U HM, IE, IND, MS, NS, null, OBX, QCF,
R, S, SDD, SYN-R, SYN-S, VS
Unknown
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DISCUSSION
In this report, we present an approach to the semantic integration
of laboratory tests and results in EHR data. Our approach connects
a widely used system for denoting laboratory tests, LOINC, with a
current standard for transmitting healthcare information, FHIR,
and a computational resource for deep phenotyping, HPO, that
was previously used mainly in the context of rare disease research
and diagnostics. Previous work such as OntoServer provides
lookup services of different terminologies and maps similar
concepts that originate from different terminologies.31 The focus
of our tool in contrast is to provide a means of interpreting the
outcomes of laboratory tests using an ontology of phenotypic
abnormalities. Normalizing laboratory tests with HPO terms is an
effective solution for two fundamental issues in clinical research:
data integration and deep phenotyping. Laboratory test results
support a large proportion of medical decisions.32 It is common
that different laboratory tests may lead to results that have very
similar or identical clinical interpretations. These different tests are
recorded in the EHR using distinct codes (for instance, currently,
there are four different LOINC terms for different tests of urine
nitrite). This level of granularity can create difficulties for the
semantic integration of comparable test results. By converting the
results of laboratory tests to HPO-encoded phenotypes, our
method provides an effective way for integrating laboratory tests
that have the same clinical interpretation but different LOINC
codes. Extracted patient phenotypes can be directly utilized for
PheWAS studies, which is important because phenotyping
patients is a major bottleneck for conducting PheWAS studies.33
The Electronic Medical Records and Genomics (eMerge) network
develops EHR-derived phenotyping algorithms by combining
diagnosis codes, procedure codes, medication, narratives, and
subsets of laboratory tests and iteratively refine them to identify
control and disease cohorts for genome-wide association studies
and PheWAS.1,3,33–35 Our method complements existing
phenotyping algorithms because it extracts additional phenotypic
information by systematically interrogating the vast amount of
data in laboratory tests.
The analysis of UNC EHR data demonstrated the potential of
combining deep phenotypes from our tool with EHR data for
biomarker discovery. Our current mapping library allowed us to
convert the majority of the laboratory tests into HPO terms and
assign an average of 57.7 unique phenotypes to each patient. The
statistical analysis identified phenotypic abnormalities that are
associated with frequent prescriptions of prednisone and/or acute
asthma diagnosis. The cohort used for this analysis is biased
toward senior and female patients and may not be reflective of
asthma patient distributions, but the fact that our analysis
identified numerous abnormalities that are associated with either
prednisone use or asthma suggests that our approach can be
useful for the investigation of EHR data for laboratory-based
biomarkers of diseases and conditions. We have demonstrated the
utility of our approach on the UNC dataset using a simple logistic
regression approach as a proof-of-principle; we envision that our
mapping approach could be used together with a variety of
statistical and algorithmic analysis strategies to address a variety
of topics in EHR-based translational research, and we have
therefore coded our foundational approach in a way that can
easily be integrated into other statistical analysis pipelines. A
particularly attractive direction is to incorporate temporal
information to build predictive models based on longitudinal
phenotypic timelines.36,37
Some practical issues need to be considered when adopting our
approach. Although LOINC has been widely adopted by health-
care providers and increasingly mandated by various federal
agencies, it is still not a universal system. Since we used LOINC for
the mapping, locally coded laboratory tests will not be able to be
mapped to HPO terms with our tools. Similarly, the SMART on FHIR
tool reported here can only be utilized in FHIR-enabled hospital
Fig. 3 Screenshot of the HPO on FHIR application. We connected the HPO on FHIR application to the SmartHealthIT R3 Sandbox (a test server
with synthetic data), queried all laboratory tests related to a simulated patient and converted all the laboratory tests into the corresponding
HPO terms. The column “# Observations” shows the counts of laboratory tests that were mapped to the same HPO term, and for multiple tests
mapped to the same HPO term, the dates of the first and last test are shown. In this example, LOINC 15074-8 was performed twice, and LOINC
2339-0 and 2345-7 were each performed once; the outcomes of all four tests were abnormally high (blood glucose), and so all four outcomes
were mapped to the HPO term Hyperglycemia (HP:0003074)
X.A. Zhang et al.
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systems. However, our annotation file and the algorithmic
approach we adopted can be used independently of FHIR.
Several other use cases for our approach are conceivable. Rule-
based algorithms could be applied to infer HPO terms from the
primary phenotypic abnormalities. For instance, the combination
of decreased hemoglobin concentration (HP:0020062) and
decreased mean corpuscular volume (HP:0025066) implies micro-
cytic anemia (HP:0001935). The HPO is widely used in rare disease
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Fig. 4 Analysis of UNC asthma dataset on asthma- and asthma-like patients. a Age and sex distribution of patients. b Categories of
information extracted from the EHR data. Cyan, used for current research; white, not used for current research. MDCTN medication, LOINC
LOINC-coded laboratory tests, VITAL vital signs, ICD 9 ICD 9-coded diagnosis, ICD 10 ICD 10-coded diagnosis, VISITS patient visit records, DEPT
clinic location, PRNT_LOC hospital location, CPT CPT-coded procedures, SOC_HIST social history, PATIENTS patient identification records,
PROVIDER provider information. c Percentage of laboratory tests in our dataset that could be converted into HPO terms (the remaining
unmapped tests did not have LOINC to HPO annotations). d Number of LOINC terms mapped to a given HPO term in the UNC dataset.
e Distribution of patients by the number of unique HPO terms that are mapped to each patient
Table 2. Odds ratio of phenotypes for frequent prednisone prescription and acute asthma diagnosis
HPO Frequent prednisone prescription Acute asthma diagnosis
Odds ratio Confidence interval (95%) P-value Odds ratio Confidence interval (95%) P-value
Abnormal metabolism 0.56 [0.26–1.23] 1.45 × 10-1 - 1.72 [1.16–2.55] 6.78 × 10-3 **
Abnormality of vitamin metabolism 0.56 [0.26–1.23] 1.45 × 10-1 - 1.72 [1.16–2.55] 6.78 × 10-3 **
Increased red blood cell count 2.48 [2–3.07] 5.42 × 10-17 ** 1.5 [1.25–1.79] 9.24 × 10-6 **
Increased VLDL cholesterol concentration 0.77 [0.38–1.53] 4.47 × 10-1 - 1.49 [1–2.23] 4.84 × 10-2 *
Abnormal VLDL cholesterol concentration 0.72 [0.36–1.44] 3.50 × 10-1 - 1.42 [0.96–2.1] 7.91 × 10-2 -
Increased hematocrit 2.42 [1.89–3.11] 2.21 × 10-12 ** 1.23 [0.99–1.53] 5.35 × 10-2 -
Abnormal eosinophil count 3.72 [3.17–4.37] 1.42 × 10-59 ** 1.17 [1.01–1.36] 3.06 × 10-2 *
Abnormal eosinophil morphology 3.72 [3.17–4.37] 1.42 × 10-59 ** 1.17 [1.01–1.36] 3.06 × 10-2 *
Eosinophilia 3.74 [3.19–4.39] 7.58 × 10-60 ** 1.17 [1.01–1.36] 3.14 × 10-2 *
Reduced blood urea nitrogen 2.35 [2.01–2.76] 6.46 × 10-27 ** 1.08 [0.95–1.24] 2.40 × 10-1 -
Increased LDL cholesterol concentration 0.81 [0.57–1.15] 2.28 × 10-1 - 1.07 [0.86–1.33] 5.39 × 10-1 -
Hypercholesterolemia 2.99 [2.58–3.47] 5.62 × 10-48 ** 1.05 [0.93–1.19] 4.48 × 10-1 -
Abnormal LDL cholesterol concentration 0.85 [0.61–1.19] 3.33 × 10-1 - 1.02 [0.82–1.26] 8.71 × 10-1 -
**P < 0.01, *P < 0.05, -P ≥ 0.05; table is sorted by the odds ratio for acute asthma diagnosis. Only HPO terms of which the odds ratio > 1 for acute asthma
diagnosis are shown. Refer to Supplementary Table 3 for all terms
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diagnostics, but one bottleneck is that in many settings, HPO
terms need to be entered manually into the analysis software. A
recent study used text-mining to extract detailed patient
phenotypes through natural language processing of clinical
narratives in EHR, and used the resulting lists of HPO terms for
genomic diagnostics.11 Our tool could supplement such
approaches by providing a computational representation of
laboratory findings to genomic diagnostic software such as
Exomiser.38–40 In principle, our tool could be used to support
other tasks related to EHR data, including decision support and
cohort recruitment. In the future, we anticipate that semantic
integration of a wider range of EHR data will become the norm to
support data-driven translational research and precision medicine.
METHODS
Mapping LOINC terms to HPO terms
We performed manual biocuration to construct a mapping library from
each potential outcome of a LOINC test to the corresponding HPO term
(Fig. 1a). The test outcome is represented using a subset of FHIR codes
(Table 1, primary code), such as “lower than normal”, “normal”, or “higher
than normal”. For quantitative tests that report a numeric measurement,
we use FHIR interpretation code “L” and “H” to indicate lower or higher
than normal, and “N” and “A” to indicate the result is normal or abnormal.
For ordinal tests that have a binary outcome, i.e., present or absent of the
test target, we use FHIR interpretation code “POS” to indicate present and
“NEG” to indicate absent. In addition, other interpretation codes defined by
FHIR are first mapped to primary codes. For example, FHIR codes “LL”
(critically low) and “<” (off scale low) are both mapped to “L” (Table 1).
The value for a map entry is an HPO term accompanied by a boolean
value to indicate whether it should be negated. That is, while an abnormal
test outcome is mapped to a particular HPO term, the normal outcome for
that test is mapped to the negated form, since the HPO contains only
terms for abnormal phenotypes. Figure 1a shows three examples of
mappings for Qn, Ord, or Nom LOINC terms.
In order to efficiently perform the biocuration needed to generate the
LOINC mappings, we developed a JavaFX-based annotation tool that
recommends candidate HPO terms to a LOINC test based on lexical
matching between HPO term definitions and the name of a laboratory test.
The recommended HPO terms were then manually vetted by one of five
biocurators (i.e., one MD and four PhDs who have biomedical training and
are major contributors to the HPO project) and cross-validated by a
different annotator. Mapping problems were tracked by Github issues
(https://github.com/TheJacksonLaboratory/loinc2hpoAnnotation/issues)
and discussed during regular meetings. Source code and an executable
version of the biocuration application are freely accessible at https://
github.com/monarch-initiative/loinc2hpo. In addition, a subset (n= 160) of
pediatric-specific laboratory tests were independently validated by five
domain experts (i.e., three pediatric clinicians, a PhD-level molecular
biologist, and a master’s-level epidemiologist). To perform this validation, a
Qualtrics survey was designed so that each question featured a laboratory
test description and set of reasonable HPO concepts. The survey was
completed by all experts between October and December (2019). After
completion, any laboratory test mapping that did not meet agreement by
at least one clinician and both the biologist/epidemiologist were re-
evaluated with one clinician until consensus was reached. The pediatric
terms were additionally vetted on the loinc2hpoAnnotation GitHub tracker
by the entire team of biocurators.
LOINC to HPO mapping file
The LOINC to HPO mapping file contains records of mapping from LOINC
test outcomes to the corresponding HPO terms. The annotation data are
serialized as a tab-separated value (TSV) file. Each line records the LOINC
code, test outcome, the mapped HPO term, and whether the mapped term
should be negated. The annotation file is deposited at Github and can be
accessed at https://w3id.org/loinc2hpo/annotations. An excerpt is shown
in Supplementary Table 1.
HPO on FHIR
We created a SMART on FHIR application, HPO on FHIR, to query a FHIR-
enabled EHR servers and return patient laboratory results with
LOINC codes and their corresponding HPO terms. The web interface of
the application aggregates identical HPO terms together for visualization
and also allows users to display source laboratory tests including subject,
LOINC code, FHIR resource id, effective time and the corresponding
HPO term. The application was written in the Java language
with the Spring framework. The application implements the LOINC to
HPO conversion algorithm described in Supplementary Fig. 1. The
application is deposited at Github and can be accessed at (https://
github.com/OCTRI/poc-hpo-on-fhir).
Command-line application for gathering FHIR server statistics
We created a command-line application that finds all laboratory tests for a
patient on a FHIR server and attempts to convert them to HPO. The
conversion results, both successes and failures, are stored in a relational
database to aid in translational research. We ran the application on seven
common FHIR sandboxes and gathered statistics about the LOINCs
encountered, the rate of success in conversion, and the underlying causes
of failure. The application was written in the Java language with the Spring
framework. Source code, results, and a backup of the database, can be
accessed at https://github.com/OCTRI/f2hstats.
Analysis of UNC data on patients with asthma or an asthma-like
condition
For the purposes of demonstrating the potential utility of our library, we
examined a de-identified EHR dataset extracted from the Carolina Data
Warehouse for Health (CDWH) at the UNC. The data were accessed under a
fully executed Data Use Agreement between The Jackson Laboratory and
UNC. The CDWH is UNC Health Care System’s (UNCHCS) enterprise data
warehouse, and contains EHR data for all UNCHCS patients from 2004
through 2016. The sample used for this investigation contains 15,681
patients with one or more encounters at UNCHCS with an asthma or
asthma-like diagnosis (Supplementary Table 2). The data were exported
from the UNC EHR system as eight separate comma-separated value (CSV)
files containing clinical observations in a variety of data domains, including
demographics, encounter details, diagnoses, procedures, medications, vital
signs, and LOINC-coded lab results. Prior to transmission from UNC, the
dataset was de-identified according to the Safe Harbor method of the
Health Insurance Portability and Accountability Act (HIPAA), and all dates
were shifted ±50 days. The project methods and use of the de-identified
EHR-derived dataset were reviewed by The Jackson Laboratory Institu-
tional Review Board and confirmed to be compliant with relevant
guidelines and regulations and approved for data access on 19
December 2017.
Using the extracted laboratory data, we converted each LOINC-coded
test into an HPO term. We note, however, that not every laboratory test
result was captured in the available dataset. For each patient, we
combined test records mapped to the same HPO terms and recorded
the counts of observations for each HPO term. Then, we inferred additional
phenotypic abnormalities based on the hierarchical structure of HPO, i.e., if
a patient was assigned with an HPO term, we infer that the patient also
had phenotypic abnormalities encoded by parent and other ancestor
terms (Supplementary Fig. 2). We reasoned that an isolated abnormal
measurement might represent an artifact or might not be typical of the
clinical course of the patient, and therefore used a threshold of three
observations over the entire observation period in order to classify a
patient with the corresponding HPO-encoded phenotypic abnormality. We
classified a patient not having an HPO-encoded phenotypic abnormality
only when the patient had never been assigned to the HPO term in
question. Patient age was calculated from the last hospital visit date
subtracting the birth date and is subject to an inaccuracy of ±50 days due
to the deidentification procedure (see above). Patients who rarely visited
hospitals were less likely to receive laboratory tests and thus had less
phenotypes, so we excluded those who had medical encounters on
<10 days. Patients received >3 prednisone prescriptions were considered
frequent users.
Statistics
We applied a logistic regression model to determine the weights of being
a frequent prednisone user (values 0 or 1) and having an acute asthma
diagnosis (values 0 or 1) in determining a patient having an HPO-encoded
phenotype (values 0 or 1). We excluded HPO terms from analysis of which
the majority (95%) of the cohort had universal values (all 0 or 1). The
X.A. Zhang et al.
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natural exponential of the weights ± 1.98 standard deviations were
converted to the odd ratio and 95% confidence intervals for each variable.
Data cleaning, normalization, wrangling, and table joining were
conducted by a combination of “tidyverse”, “RSQLite” packages in R,
SQLite, and Java. Logistic regression was conducted with the “glm”
package in R. All source code is deposited at Github and can be accessed
through https://github.com/TheJacksonLaboratory/HUSHDataAnalysis.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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